Inflection Biosciences Announces Pre-clinical data for IBL-101 to be Presented at BSI Congress 2022
Dublin, Ireland, December 5, 2022 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...
top of page
Developing Innovative Therapeutics
Our Company
Inflection Biosciences is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory disease. The pipeline comprises of IBL-101, an oral, pan-PIM kinase inhibitor in development for autoimmune and inflammatory disease, IBL-202, selected from a series of unique dual mechanism kinase inhibitors and AUM302 (formerly IBL-302), partnered with AUM Biosciences.
bottom of page